9 results about "Vinorelbine" patented technology

Disclosed are methods of treating cancer with a tri-agent therapy. The methods include a cancer treatment regimen with two or three different antineoplastic medications, including tamoxifen, gefitinib, and vinorelbine (TGV). The cancer treatment regimen can include sequential and / or concurrent administration of tamoxifen, gefitinib, and vinorelbine. The cancer treatment regimen can include sequential and / or concurrent administration of tamoxifen and gefitinib as adjuvants to a prescribed treatment. The cancer treatment regimen can be cyclical or can be a continuous metronomic treatment with metronomic dosing. The cancer treatment regimen can be cyclical and then can be followed by a continuous metronomic treatment with metronomic dosing.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

The invention discloses a method for detecting the content of fumaric acid vonoprasan in a fumaric acid vonoprasan tablet, which comprises the following steps: carrying out ultrahigh liquid chromatography detection on a sample to be detected, and determining the content of fumaric acid vonoprasan in the sample to be detected on the basis of a detection result, a mobile phase adopted in the ultrahigh liquid chromatography detection comprises a phosphate buffer solution and methanol, and the volume ratio of the phosphate buffer solution to the methanol is (50-70): (30-50); the elution mode is isocratic elution. According to the detection method, an isocratic elution mode is adopted, the treatment mode is simple, the detection operation time is short, and consumed resources are fewer; the phosphate buffer solution and the methanol in a specific ratio are used as mobile phases, so that the method has the advantages of strong qualitative specificity, accurate quantification, high sensitivity, good method stability, short operation time, high efficiency, rapidness, high detection efficiency and the like, and can realize effective detection of the content of the Vonoprazan fumarate in the Vonoprazan fumarate tablets.

To provide uses of pertuzumab, which is a first in-class HER2 dimerization inhibitors, and articles of manufacture comprising the same.SOLUTION: A method for extending progression free survival in a population of HER2 + breast carcinoma patients; a method for combining two HER2 antibodies to treat HER2 + breast carcinoma without increasing cardiotoxicity; a method for treating early HER2 + breast carcinoma; a method for treating HER2 + breast carcinoma by co-administering a mixture of pertuzumab and trastuzumab from the same I. v. bag; a method for treating HER2 + metastatic gastric carcinoma; a method for treating HER2 + breast carcinoma with pertuzumab, trastuzumab and vinorelbine; Methods for treating HER2 positive breast cancers with trastuzumab and aromatase inhibitors; and methods for treating low HER3 ovarian, primary peritoneal, or fallopian tube cancers are provided.SELECTED DRAWING: None

The invention discloses an application of ametinib or vomitinib, endol and oral vinorelbine in preparation of a medicine for treating a IV-stage non-small cell lung cancer patient carrying EGFR sensitive mutation, and belongs to the technical field of biological medicines. Wherein the bit progression-free lifetime (PFS) is up to 32.3 months. The composition is superior to third-generation EGFR-TKI single-drug treatment in the prior art and is also superior to most reported combined schemes. In addition, the PFS rates of 1 year, 2 years and 3 years are respectively as high as 91.7%, 66.7% and 41.7%, indicating that the scheme in the invention can provide lasting and stable disease control.

The present application relates to ligands targeted to epidermal growth factor receptor (EGFR) and compositions for use in treating tumors. Specifically, a ligand targeted to EGFR is disclosed. The ligand comprises a heavy chain variable domain and a light chain variable domain. The ligand may be selected from the group consisting of a single chain variable fragment, a fusion protein, a monoclonal antibody, and an antigen-binding fragment thereof. The ligand may be conjugated to a liposome or a nanoparticle that encapsulates at least one chemotherapeutic agent to form a ligand-targeted liposomal or nanoparticle drug. Also disclosed are conjugates and formulations for use in treating tumors such as squamous cell carcinoma of head and neck. A method for making a ligand-targeted liposomal drug is also disclosed. The drug may be a chemotherapeutic agent selected from the group consisting of doxorubicine and vinorelbine.

The application belongs to the technical field of medical animal model modeling, and provides a simple and easy-to-operate model construction method which can simulate the characteristics of clinical chemotherapy phlebitis to solve the problems of complicated replication method and lack of clinical typical characteristics of the current chemotherapy phlebitis animal model. The model agent is administered to the dorsal vein of the rat foot, and the best replication scheme of the chemotherapy phlebitis rat model is determined by investigating the concentration, dose and duration. The chemotherapy phlebitis rat model is replicated by using vinorelbine physiological saline solution with a concentration of 2-5 mg / ml and a total dose of ≤3 mg / kg. The local characterization of the dorsal foot and the foot swelling rate on the next day after modeling meet the diagnostic criteria of chemotherapy phlebitis. The pathological characteristics of chemotherapy phlebitis can be observed in the blood vessel pathological section under a light microscope and an intima scanning electron microscope, and the duration is 7 days. The model has the advantages of simple preparation method, clear quality control index, long maintenance time, low preparation cost and close to human diseases.

The invention relates to the technical field of medicine purification, in particular to a refining method of high-purity Vonoprazan fumarate. The invention relates to a refining method of high-purity Vonoprazan fumarate, which comprises the following steps: S1, adding a polar solvent, water and lauryl sodium sulfate into a reaction bottle, and uniformly stirring; s2, adding a Vonoprazan fumarate crude product, heating and dissolving, and adding activated carbon; s3, filtering while the solution is hot, and stirring, cooling and separating out solids; s4, filtering and vacuum drying are carried out, and the high-purity Vonoprazan fumarate is obtained. According to the refining method of the Vonoprasone fumarate, the final product is obtained through one-time recrystallization, and the purity of the product is gt; therefore, the pharmaceutical quality standard is met. According to the refining method of the Vonoprazan fumarate, process impurities U2-U5 which are difficult to remove by a conventional recrystallization method can be removed, and the refining method is good in impurity removal effect, high in yield, simple to operate, few in three wastes and suitable for industrial production requirements.

The invention provides a method for detecting genotoxic impurities in a Vonoprazan fumarate preparation, the genotoxic impurities are pyridine ring N-oxides, and the structure of the genotoxic impurities is shown as a formula I. The invention further provides a method for detecting the genotoxic impurities in the Vonoprazan fumarate preparation. The detection method comprises the following steps: mixing a to-be-detected sample with an extraction solvent, performing vortex, performing centrifugation, performing filtration, taking a subsequent filtrate, and performing dilution so as to obtain a test solution; mixing an impurity reference substance with an acetonitrile aqueous solution to obtain a reference substance solution; and performing high performance liquid chromatography detection on the test solution and the reference solution, and determining the content of the genotoxic impurities according to a detection result. The method provided by the invention has the advantages of short peak appearance time, beautiful peak shape, good separation degree, high sensitivity, high accuracy, good durability and the like, is low in quantitation limit and detection limit, can rapidly and effectively detect trace potential genotoxic oxidation impurities in the Vonoprasone fumarate tablets, can efficiently realize quantitative analysis of the oxidation impurities, and has a wide application prospect. The method has important practical significance on the quality control of the fumaric acid Vonoprazan tablets.